CD8A and neoplasm: In a study by Yost et al., scRNA/TCR-Seq analysis of metastatic basal/squamous cell carcinoma patient TIL before and after ICB indicated that clonal replacement dominated the response where upwards of 84% of CD8+ T cell clonotypes (having a single TCR specificity) present after treatment were novel (i.e., not present in the tumor before treatment) (72).